Vesselon acquires FDA-approved Lipid Microsphere Drug Imagent for therapeutic platform

This article was originally published here

Vesselon will use Imagent to create novel therapeutic complexes in four classes of cancer drugs: cytokines, oncolytic viruses, monoclonal antibodies, and nucleic acid constructs. Vesselon incorporates Imagent into

The post Vesselon acquires FDA-approved Lipid Microsphere Drug Imagent for therapeutic platform appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply